• SENSEX
    NIFTY 50
Business

IPCA Labs stock up 40% in 2019: Here is why the scrip has outperformed benchmarks

Updated : November 19, 2019 02:44 PM IST

IPCA is a rare case of outperformance; the stock has given returns despite facing USFDA compliance issues.
The company also seems to be rediscovering its mojo in the institutional malaria business.
IPCA Labs stock up 40% in 2019: Here is why the scrip has outperformed benchmarks

You May Also Like

Live TV
Advertisement